VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Targeting low HER2 expression with antibody-drug conjugates

Giuseppe Curigliano • 19 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Lapatinib Trastuzumab Trastuzumab deruxtecan

Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses low HER2 expression metastatic breast cancer and its treatment with antibody-drug conjugates. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Giuseppe Curigliano

3:29
Designing innovative clinical trials in BC
Giuseppe Curigliano • 18 May 2020
5:40
Looking back on COVID in order to move forward
Giuseppe Curigliano • 28 May 2020
1:20
Molecular drivers of metastatic disease in breast cancer
Giuseppe Curigliano • 26 Sep 2015
2:42
Biomarker-driven therapies for triple-negative breast cancer
Giuseppe Curigliano • 26 Sep 2015

Related Videos

8:01
Immune oncology in breast cancer: KEYNOTE-086, NCI 10013, & AIPAC
Sangeetha Reddy • 16 Dec 2020
2:36
Tailoring medicine in breast cancer
Erika Hamilton • 15 Dec 2020
2:09
MARIO-3: eganelisib in TNBC
Erika Hamilton • 15 Dec 2020
1:14
HER2CLIMB: outcomes by hormone receptor status
Erika Hamilton • 15 Dec 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals